Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pemetrexed disodium
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 276 for your search:
Start Over
Chemotherapy for Patients With Non-Small Cell Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10720, H3E-MC-JMIC, NCT00380718
A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12628, H3E-JE-JMII, NCT01020786
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: CH-BC-008, NCT01143974
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: IFCT-GFPC-0701, NCT00651456
TAilored Post-Surgical Therapy in Early Stage NSCLC
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: IFCT-0801, Eudract : 2008-004939-38, NCT00775385
A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8433, H3E-MC-JMGX, NCT00078260
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2938, H3E-MC-JMDB, NCT00087711
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13423, I4E-MC-JXBC, CP02-0452, NCT00095199
Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 5122, H3E-MC-JMEN, NCT00102804
Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: I05026, NCT00284778
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00509, ECOG-E1505, CDR0000475774, E1505, U10CA180820, U10CA021115, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10717, H3E-MC-JMID, NCT00391274
A Study for Patients With Head and Neck Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8431, H3E-MC-JMHR, NCT00415194
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00036, EUDRACT No. 2006-003695-35, NCT00418886
Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CT/06.05, NCT00440414
Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11626, H3E-CR-S380, NCT00520676
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO18602, NCT00556322
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11514, H3E-MC-JMIG, NCT00686959
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00663, CDR0000612010, NCCTG-N0723, CALGB-30802, CAN-NCIC-BRC4, N0723, U10CA025224, MARVEL, NCT00738881
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9707, H3E-MC-JMHD, NCT00762034
A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12560, H3E-EW-S124, CTRI/2009/091/000113, NCT00789373
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1199.14, 2008-002072-10, NCT00806819
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000636895, CALGB-30506, NCT00863512
Start Over